About this trial
Using a randomized controlled design, the project aims to test if cognitive behavioral therapy interventions specifically targeting sleep disorders can significantly lessen the burden of the disrupted sleep in patients with treatment resistant schizophrenia (TRS) and by proxy lead to a reduction in psychotic symptoms and improvement in quality of life.
We are including treatment-resistant patients with schizophrenia other nonorganic and chronic psychoses and in addition meeting the criteria of a sleep or circadian disorder. Included patients will be block randomized to either 8-10 sessions of CBT-I (active treatment) with a specific focus on sleep or 8-10 sessions of regularCBT with a specific focus on patients' psychopathology (treatment as usual) approx.1 session/week.
After 12 weeks the full battery of assessments will be repeated forboth groups. Primary analyses will be to identify group-difference in changes using repeated measure ANOVA.
Eligibility criteria
Qualifiers
Diagnosed with ICD-10 schizophrenia (DF20), chronic paranoid psychosis (DF22), schizo-affective disorder (DF25) or other non-organic psychosis (DF28-DF29)
Treatment resistance according to TRRIP criteria
Sleeping difficulties (minimum duration 3 months)
ISI score >14
Disqualifiers
Psychiatric admission last six months (more than 1 week or resulted in significant changes in psychopharmacological treatment)
Substance abuse to a degree that will interfere with participation.
Diagnoses of sleep apnea/CPAP use
Trial design
Treatments tested in this trial
- CBT-I
- CBT
Treatment groups
Sponsors and collaborators
Jimmi Nielsen
Lead sponsor
Copenhagen University Hospital, Hvidovre
Sponsor institution